Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Multicentric Study for External Validation of a Deep Learning Model for Mammographic Breast Density Categorization

19. August 2021 aktualisiert von: Hospital Italiano de Buenos Aires
The correct categorization of breast density is essential to adapt the diagnostic examination to the needs of each patient. Assessment of breast density is performed visually by radiologists. Some authors have detected that this method involves considerable intra and interobserver variability. On the other hand, automated systems for measuring breast density are becoming more and more frequent. Machine learning is a domain of Artificial Intelligence, which comprises the process of developing systems with the ability to learn and make predictions using data. These systems are designed to aid healthcare professional decision making. In the present work, the multicenter study of external validation of a tool based on deep learning for the categorization of mammographic breast density is proposed.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Detaillierte Beschreibung

The correct categorization of breast density is essential to adapt the diagnostic examination to the needs of each patient. Assessment of breast density is performed visually by radiologists. Some authors have detected that this method involves considerable intra and interobserver variability. On the other hand, automated systems for measuring breast density are becoming more and more frequent. Consequently, in clinical practice, breast density is reported from the assessment carried out by specialists with the support of these systems. But there are few studies about the use, concordance and perception of usefulness of professionals on these tools. A study carried out at the Hospital Italiano de Buenos Aires reported a moderate to almost perfect inter- and intra-observer agreement among radiologists and a moderate concordance between the categorization carried out by experts and that carried out by commercial software of a digital mammography machine. Machine learning is a domain of Artificial Intelligence, which comprises the process of developing systems with the ability to learn and make predictions using data. Once a system designed to aid healthcare professional decision making is developed, it must be validated. In 2019, an internal validation of a tool based on deep learning techniques was carried out for the automatic categorization of mammographic breast density. The tool reached a very good interobserver agreement, kappa = 0.64 (95% CI 0.58-0.69), when compared with the performance of the professionals. It reached a sensitivity of 83.2 (CI: 76.9-88.3) and a specificity of 88.4 (83.9-92.0.) In the present work, the multicenter study of external validation of a tool based on deep learning for the categorization of mammographic breast density is proposed. The evaluation of this tool will be carried out in two external institutions: Hospital Alemán and Fundación Científica del Sur.

Studientyp

Beobachtungs

Einschreibung (Voraussichtlich)

277

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Kind
  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

The unit of analysis will be the bilateral mammographic images with mediolateral oblique and craniocaudal views. The images selected for this study will be screening mammograms performed at Saint John's Cancer Institute. The institution will select the images according to the inclusion and exclusion criteria. The images will be extracted from the institutional database retrospectively and will be anonymized without any personal data, except for the age of the patient. These images will be stored in DICOM format, in a safe place with restricted access limited only to the investigation team.

Beschreibung

Inclusion Criteria:

  • Mammograms included in the study should meet the following criteria:

    • Female patients of 40 years of age or more.
    • To have at least one screening mammography exam performed at Saint John's
    • Cancer Institute during the study period. These exams will be included regardless of the brand of the mammography equipment.
    • Mammograms should be performed with digital equipment.

Exclusion Criteria:

  • Mammograms with the following criteria will be excluded from the study:

    • Patients with gigantomastia, defined by the need for more than one image of each mammographic view (mediolateral oblique and craniocaudal) to evaluate the entire breast volume.
    • Patients with breast implants.
    • Patients with a history of breast surgery.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Agreement between the majority report and Artemisia´s categorization of dense breasts/non-dense breasts
Zeitfenster: 2 months
The agreement between the CNN and the total of the professionals' categorizations will be calculated with the linear weighted kappa. To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by Artemisia for the same set of images.
2 months
Agreement between the majority report and Artemisia in each one of the four breast density categories
Zeitfenster: 2 months
For each one of the professionals involved in the study, the agreement with the CNN will be calculated with the linear weighted kappa coefficient. To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by Artemisia for the same set of images.
2 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Agreement between each observer and Artemisia´s categorization of dense breasts/non-dense breasts
Zeitfenster: 2 months
To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by Artemisia for the same set of images.
2 months
Agreement between each observer and Artemisia in each one of the four breast density categories
Zeitfenster: 2 months
For each one of the professionals involved in the study, the agreement with the CNN will be calculated with the linear weighted kappa coefficient. To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by Artemisia for the same set of images.
2 months
Agreement between each observer and the majority report in the categorization of dense breasts/non-dense breasts
Zeitfenster: 2 months
For each one of the professionals involved in the study, the agreement with the majority report will be calculated with the linear weighted kappa coefficient. To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by the majority report for the same set of images.
2 months
Agreement between each observer and the majority report in each one of the four breast density categories
Zeitfenster: 2 months
For each one of the professionals involved in the study, the agreement with the majority report will be calculated with the linear weighted kappa coefficient. To this end, the categories assigned by the professionals will be considered as only one observer in each one of the studies and they will be compared to those assigned by the majority report for the same set of images.
2 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Daniel R Luna, MD, Hospital Italiano de Buenos Aires

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Voraussichtlich)

1. September 2021

Primärer Abschluss (Voraussichtlich)

1. April 2022

Studienabschluss (Voraussichtlich)

1. Juli 2022

Studienanmeldedaten

Zuerst eingereicht

19. August 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

19. August 2021

Zuerst gepostet (Tatsächlich)

25. August 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

25. August 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. August 2021

Zuletzt verifiziert

1. Juli 2021

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 6077
  • 4927 (PRIISA)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Brustkrebs

3
Abonnieren